Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00882388
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
- Conditions
- Interventions
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT00808743
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱University Medical Center, Groningen, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 201
- Registration Number
- NCT00807846
- Locations
- 🇺🇸
University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States
🇨🇱Hospital Roberto del Rio, Santiago, RM, Chile
🇷🇸Institute of Rheumatology, Belgrade, Serbia
Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
- Conditions
- Interventions
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 26
- Registration Number
- NCT00780325
- Locations
- 🇺🇸
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers
- Conditions
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2008-10-23
- Lead Sponsor
- Research Associates of New York, LLP
- Target Recruit Count
- 125
- Registration Number
- NCT00778193
- Locations
- 🇺🇸
Research Associates of New York, New York, New York, United States
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 240
- Registration Number
- NCT00762463
- Locations
- 🇨🇳
Pfizer Investigational Site, Beijing, China
Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- POZEN
- Target Recruit Count
- 80
- Registration Number
- NCT00729495
- Locations
- 🇺🇸
Research, Springfield, Missouri, United States
Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- IDEA AG
- Target Recruit Count
- 1399
- Registration Number
- NCT00716547
- Locations
- 🇩🇪
Klaus-Miehlke-Klinik, Wiesbaden, Germany
🇨🇿IDEA Investigational Site, Prague 2, Czech Republic
🇵🇱NZOZ Nasz Lekarz, Torun, Poland
Cox-2 Inhibition in Radiation-induced Oral Mucositis
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 43
- Registration Number
- NCT00698204
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 275
- Registration Number
- NCT00688545
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.